Literature DB >> 12540573

Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent.

Christine A Garhart1, Frederick P Heinzel, Steven J Czinn, John G Nedrud.   

Abstract

Previous studies with mice have shown that major histocompatibility complex class II (MHC-II) is required for protection from Helicobacter pylori, while MHC-I and antibodies are not. Thus, CD4(+) T cells are presumed to play an essential role in protective immunity via secretion of cytokines. To determine which cytokines are associated with a reduction of bacterial load in immunized mice, gastric cytokine expression was examined by semiquantitative reverse transcription-PCR in protected (defined as > or =2-log-unit decrease in bacterial load) and unprotected mice 4 weeks after challenge. Elevated levels of mRNA for interleukin-12p40 (IL-12p40), gamma interferon (IFN-gamma), tumor necrosis factor alpha, and inducible nitric oxide synthase (iNOS) were associated with protection in immunized-challenged (I/C) mice, but Th2 cytokine (IL-4, IL-5, IL-10, and IL-13) and chemokine (KC, MIP-2, and MCP-1) expression was not associated with protection. Despite the association of IFN-gamma and iNOS message with protection, I/C mice genetically lacking either of these products were able to reduce the bacterial load as well as the wild-type I/C controls. The I/C mice lacking IL-12p40 were not protected compared to unimmunized-challenged mice. All I/C groups developed gastritis. We conclude that neither IFN-gamma nor iNOS is essential for vaccine-induced protection from H. pylori infection. The p40 subunit of IL-12, which is a component of both IL-12 and IL-23, is necessary for protection in immunized mice. These findings suggest a novel IFN-gamma-independent function of IL-12p40 in effective mucosal immunization against H. pylori.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540573      PMCID: PMC145373          DOI: 10.1128/IAI.71.2.910-921.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization.

Authors:  J M Gottwein; T G Blanchard; O S Targoni; J C Eisenberg; B M Zagorski; R W Redline; J G Nedrud; M Tary-Lehmann; P V Lehmann; S J Czinn
Journal:  J Infect Dis       Date:  2001-07-10       Impact factor: 5.226

2.  Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice.

Authors:  L E Smythies; K B Waites; J R Lindsey; P R Harris; P Ghiara; P D Smith
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy.

Authors:  J G Fox; P Beck; C A Dangler; M T Whary; T C Wang; H N Shi; C Nagler-Anderson
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection.

Authors:  J Ikewaki; A Nishizono; T Goto; T Fujioka; K Mifune
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

5.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

6.  Helicobacter pylori infection in wild-type and cytokine-deficient C57BL/6 and BALB/c mouse mutants.

Authors:  A E Kamradt; M Greiner; P Ghiara; S H Kaufmann
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

7.  Helicobacter pylori gastritis: a Th1 mediated disease?

Authors:  M Lohoff; M Röllinghoff; F Sommer
Journal:  J Biotechnol       Date:  2000-09-29       Impact factor: 3.307

Review 8.  The immune response against Helicobacter pylori--a direct linkage to the development of gastroduodenal disease.

Authors:  A Ibraghimov; J Pappo
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

9.  Adoptive transfer of CD4+ T cells specific for subunit A of Helicobacter pylori urease reduces H. pylori stomach colonization in mice in the absence of interleukin-4 (IL-4)/IL-13 receptor signaling.

Authors:  B Lucas; D Bumann; A Walduck; J Koesling; L Develioglu; T F Meyer; T Aebischer
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients.

Authors:  N Agnihotri; D K Bhasin; H Vohra; P Ray; K Singh; N K Ganguly
Journal:  Scand J Gastroenterol       Date:  1998-07       Impact factor: 2.423

View more
  24 in total

1.  Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.

Authors:  Carl-Fredrik Flach; Anna Karin Östberg; Anne-Therese Nilsson; Rene De Waal Malefyt; Sukanya Raghavan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses.

Authors:  Holly M Scott Algood; Timothy L Cover
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Authors:  John G Nedrud; Nayer Bagheri; Karin Schön; Wei Xin; Hilda Bergroth; Dubravka Grdic Eliasson; Nils Y Lycke
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 4.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

Review 5.  Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma.

Authors:  Mathijs P Bergman; Mario M D'Elios
Journal:  J Biomed Biotechnol       Date:  2010-06-22

6.  Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice.

Authors:  Marianne Quiding-Järbrink; Sukanya Raghavan; Malin Sundquist
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

7.  Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice.

Authors:  John Y Kao; Min Zhang; Mark J Miller; Jason C Mills; Baomei Wang; Maochang Liu; Kathyn A Eaton; Weiping Zou; Bradford E Berndt; Tyler S Cole; Tomomi Takeuchi; Stephanie Y Owyang; Jay Luther
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

8.  Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1{beta}.

Authors:  Akinobu Kajikawa; Kazuya Masuda; Mitsunori Katoh; Shizunobu Igimi
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

9.  NF-kappaB activation during acute Helicobacter pylori infection in mice.

Authors:  Richard L Ferrero; Patrick Avé; Delphine Ndiaye; Jean-Christophe Bambou; Michel R Huerre; Dana J Philpott; Sylvie Mémet
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

10.  Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4.

Authors:  Christine A Garhart; John G Nedrud; Frederick P Heinzel; Norma E Sigmund; Steven J Czinn
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.